Novavax Inc (NASDAQ:NVAX)
| 12.02 Delayed Data As of 4:00pm ET |  +0.78 / +6.94%Today’s Change | 8.75 Today|||52-Week Range 101.39 | +16.93% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $960.2M |
Company Description
Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Contact Information
Novavax, Inc. 21 Firstfield Road Gaithersburg Maryland 20878 |
Employees
Shareholders
| Mutual fund holders | 25.03% |
| Other institutional | 19.99% |
| Individual stakeholders | 0.29% |
Top Executives
| John C.s Jacobs | President, Chief Executive Officer & Director |
| Richard Crowley | Chief Operating Officer & Executive Vice President |
| James Patrick Kelly | Chief Financial Officer, Treasurer & Executive VP |
| Gale E. Smith | Chief Scientist & Senior Vice President-Discovery |
| Gregory M. Glenn | President-Research & Development |
